TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06040840
Drug: Lidocaine + Epinephrine
Normalized name: epinephrine / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: WALANT technique with lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine.
Study: NCT04732845
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60mg/Kg on day -6
Study: NCT04750954
Drug: Peposertib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06601218
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 months of daily dosing with oral placebo
Study: NCT06601218
Drug: Oral cannabis THC/CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 months of daily dosing with oral cannabis with THC and CBD
Study: NCT06595706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing only Silicified Microcrystalline Cellulose
Study: NCT06655194
Drug: Acetylsalicylic Acid (Aspirin, BAYE004465, UI1610477)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable tablet, 81mg, oral
Study: NCT06655194
Drug: Acetylsalicylic Acid (BAYE004465, UI1615160)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable tablet, 81 mg, oral
Study: NCT06340568
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV bolus or infusion
Study: NCT05639114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo s.c. monthly
Study: NCT05819502
Drug: Restylane line of injectables
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restylane fillers are manufactured by Q-Med AB, part of the Galderma Group.
Study: NCT06592833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo.
Study: NCT06602453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as per pre-defined regimen.
Study: NCT00124111
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00124111
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06568692
Drug: PCS6422 and capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer.
Study: NCT06568692
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Commercially available capecitabine is a commonly used oral fluoropyrimidine.
Study: NCT04921189
Drug: The combined supplement of Ascorbic acid, Thiamine, and Cortisol
Approvals — FDA: no, EMA: no, PMDA: no
Description: The combined administration of 3 drugs will be mixed in a 50 mL 0.9% saline bag respectively and administered through intravenous infusion over 60 min every 12 h for 3 days.~1. Ascorbic acid (Ascorbic acid Inj \[500mg\]®): 50 mg/kg, maximum single dose 3 g, daily dose 6 g~2. Thiamine (Thiamine hcl inj \[50mg\]®): 200 mg~3. Cortisol (Cortisolu inj \[100mg\]®): 100mg (The main exposure was corticosteroid therapy, defined as the use of systemic corticosteroids. But if unavailable, it could be converted to hydrocortisone-equivalent doses (methylprednisolone 1:5, dexamethasone 1:25, prednisolone 1:4).)
Study: NCT04921189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An identical volume of 0.9% saline (150mL) administered through intravenous infusion over 60 min every 12 h for 3 days.
Study: NCT05814432
Drug: L-AmB standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (3 mg/kg for two weeks) with liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS
Study: NCT06374459
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients should take capecitabine at approximately the same times every day, within 30 minutes after a meal.
Study: NCT06374459
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Standard of care. Will receive zoledronic acid or denosumab.
Study: NCT06506136
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive fluoxetine tablets, 20 mg each, taken orally twice a day (total daily dose of 40 mg) for 12 weeks. Tablets should be taken with water at the same times daily.~Emergency Rescue Medications: For participants in both groups who cannot have a bowel movement for three consecutive days or have intolerable symptoms, the following rescue medications will be provided:~Bisacodyl: 5-10 mg Glycerin Enema: 110 ml Polyethylene Glycol: 10 g Use of rescue medications must be recorded in the bowel movement diary and CRF, including date, time, and dosage. Rescue medications will be provided throughout the study but are not allowed within 48 hours before and after the first treatment. Distributed every two weeks, any bowel movements within 24 hours after rescue medication use will not count as CSBM.
Study: NCT06506136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the Placebo Control Group will receive placebo tablets that are identical in appearance and taste to the fluoxetine tablets. They will take one placebo tablet orally twice a day for 12 weeks, following the same schedule as the treatment group to maintain blinding.~Emergency Rescue Medications: For participants in both groups who cannot have a bowel movement for three consecutive days or have intolerable symptoms, the following rescue medications will be provided:~Bisacodyl: 5-10 mg Glycerin Enema: 110 ml Polyethylene Glycol: 10 g Use of rescue medications must be recorded in the bowel movement diary and CRF, including date, time, and dosage. Rescue medications will be provided throughout the study but are not allowed within 48 hours before and after the first treatment. Distributed every two weeks, any bowel movements within 24 hours after rescue medication use will not count as CSBM.
Study: NCT06501664
Drug: LV
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: LV 400 mg/m²
Study: NCT06144983
Drug: Alvogyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the first study group, (0.2gm) of Alvogyl paste (Septodont Inc., France), was inserted inside the alveolus, filling it entirely
Study: NCT05174000
Drug: Test Euthyrox®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single oral dose of Test Euthyrox® either in treatment period 1, 2, 3 or 4.
Study: NCT05174000
Drug: Reference Euthyrox®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single oral dose of Reference Euthyrox® either in treatment period 1, 2, 3 or 4.
Study: NCT00000873
Drug: Infant Formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05826327
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil for labour analgesia in the control group
Study: NCT06627257
Drug: LepVax (2 μg LEP-F1 + 5 μg GLA-S): Low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.
Study: NCT06627257
Drug: LepVax (10 μg LEP-F1 + 5 μg GLA-SE): High dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.
Study: NCT05304585
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00002105
Drug: Doxorubicin hydrochloride (liposomal)
Normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05438264
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05047536
Drug: KZR-261
Approvals — FDA: no, EMA: no, PMDA: no
Description: KZR-261 for Injection is a lyophilized drug product supplied in single-use vials delivering 75 mg of KZR-261.
Study: NCT05594095
Drug: AKT inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKT inhibitor
Study: NCT06128967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo talc pills of same shape, color, weight if compared with active comparator
Study: NCT05539157
Drug: JCXH-211
Approvals — FDA: no, EMA: no, PMDA: no
Description: JCXH-211 administered once every 28 days
Study: NCT05172739
Drug: Opioid-Based Anesthesia-Analgesia Strategy
Normalized name: OPIOID ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: A perioperative Opioid-Based multimodal Anesthesia- Analgesia strategy will be implemented that incorporates the following pharmacological agents:~Premedication: Midazolam, Anaesthesia induction \& maintenance: Midazolam, Propofol, Fentanyl, Cisatracurium or alternatively Rocuronium, Desflurane, Morphine, Paracetamol, Dexketoprofen trometamol, Ondansetron or Droperidol, Ropivacaine Surgical ward: Morphine, Paracetamol, Dexketoprofen trometamol Rescue therapy only: Tramadol
Study: NCT05172739
Drug: Opioid-free Anesthesia-Analgesia Strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: A perioperative Opioid-Based multimodal Anesthesia- Analgesia strategy will be implemented that incorporates the following pharmacological agents:~Premedication: Pregabalin, Midazolam, Anesthesia induction \& maintenance: Midazolam, Dexmedetomidine, Lidocaine, Propofol, Ketamine, Hyoscine, Cisatracurium or alternatively Rocuronium, Magnesium sulphate, Dexamethasone, Desflurane, Paracetamol, Dexketoprofen trometamol, Ondansetron or Droperidol, Ropivacaine, Surgical ward: Ketamine, Lidocaine, Clonidine, Droperidol and Midazolam, Pregabalin, Paracetamol, Dexketoprofen trometamol Rescue therapy only: Tramadol
Study: NCT05778097
Drug: Androgen deprivation therapy(ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of ADT will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
Study: NCT05243251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 300 mg of microcrystalline cellulose. It will be identical to the active drug
Study: NCT06287320
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-1/anti-PD-L1 immune checkpoint inhibitors
Study: NCT05099640
Drug: PTC923
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC923 powder for oral use will be suspended in water or apple juice prior to administration.
Study: NCT05099640
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to PTC923
Study: NCT05315921
Drug: OsrhAAT 10 mg/kg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: : OsrhAAT 10 mg/kg IV A single dose of OsrhAAT 10 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)
Study: NCT05315921
Drug: OsrhAAT 20 mg/kg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: OsrhAAT 20 mg/kg IV A single dose of OsrhAAT 20 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)
Study: NCT05315921
Drug: OsrhAAT 40 mg/kg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: OsrhAAT 40 mg/kg IV A single dose of OsrhAAT 40 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)
Study: NCT05315921
Drug: OsrhAAT 60 mg/kg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: OsrhAAT 60 mg/kg IV A single dose of OsrhAAT 60 mg/kg IV infusion at a rate approximately 0.04 ml/min/kg.~Placebo: Normal Saline (0.9% Sodium Chloride)
Study: NCT05571592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo~Placebo softgel capsule formulation.
Study: NCT04409873
Drug: Oral-B Mouth Sore mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinse and gargle 4 times daily, for 60 seconds, for 4 weeks.
Study: NCT04409873
Drug: CloSYS Ultra Sensitive Rinse mouthwash
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinse and gargle 4 times daily, for 45 seconds, for 4 weeks.
Study: NCT06025097
Drug: Combination Solution
Normalized name: Combination solutions for parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl Prednisone (Trade name: SOLU-MEDROL) + Platelet rich Plasma (Autologous Biological product) via intra-tympanic rout about 1-1.5 ml.
Study: NCT04409873
Drug: Listerine Zero Mouthwash Product
Normalized name: Listerine Mouthwash Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinse and gargle 4 times daily, for 30 seconds, for 4 weeks.
Study: NCT06443944
Drug: Cretostimogene Grenadenorepvec
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engineered Oncolytic Adenovirus
Study: NCT04755127
Drug: Intra-articular corticosteroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection with 40mg triamcinolone acetonide (kenacort) in the wrist
Study: NCT05114720
Drug: standard adjuvant chemotherapy plus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel 75mg/m\^2, or nab-paclitaxel 260mg/m\^2, IV, days 1 cyclophosphamide 1000 mg/m\^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m\^2, IV, days 1, cycled every 21 days cyclophosphamide 600 mg/m\^2, IV, days 1, cycled every 21 days docetaxel 100 mg/m\^2, IV, days 1, cycled every 21 days; plus Placebo 0.4 PO once daily days 1-5; cycled every 21 days
Study: NCT04592315
Drug: Lipovirtide Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dosage of Lipovirtide Injection
Study: NCT04222023
Drug: Intravenous immunoglobulins (IVIG)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group: administration of a single dose of IVIG at:~* Day 10+/- 4 days~* Day 41 +/- 7 days~* Day 62 +/- 7 days The dose of IVIG is defined according the donor BKV genotype: genotype I: 0.4 g/Kg/day; genotype II and IV: 1g/kg/day.
Study: NCT06013150
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in Part 1 of the study will receive single dose either 1mg, 1.3mg or 1.5mg of an inhaled single dose of Epinephrine or placebo delivered via DMC-IHI device.
Study: NCT06013150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant in Part 1 of the study will receive matching doses of placebo
Study: NCT04849390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration in the evening at bedtime for 28 days
Study: NCT05288920
Drug: Transforaminal injection of Steroids alone
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal injection of Steroids alone
Study: NCT06561607
Drug: TQB2102 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2102 is a next-generation HER2 Antibody-Drug Conjugate (ADC) drug proposed for patients with HER2 low-expressing breast cancer.
Study: NCT06139029
Drug: 3% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebulization
Study: NCT06139029
Drug: steroid(beclomethasone dipropionate 400 μg/day) and salbutamol with 0.9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebulization
Study: NCT05249374
Drug: Recombinant Human Serum Albumin
Normalized name: RECOMBINANT HUMAN SERUM ALBUMIN ORYZA SATIVA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/bottle (20%, 50 mL)
Study: NCT05548465
Drug: Remifentanil Hydrochloride
Normalized name: Remifentanil Hydrochloride
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive remifentanil anesthesia for operative analgesia.
Study: NCT05548465
Drug: Sufentanil Citrate
Normalized name: Sufentanil Citrate
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive sufentanil and remifentanil anesthesia for operative analgesia.
Study: NCT05289440
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received a bolus infusion of the same volume saline before cutting the skin, and then the same volume saline was infused until before suture the skin.
Study: NCT05043506
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor monotherapy
Study: NCT04632108
Drug: ASKB589 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASKB589 Injection with dose escalation stage of 0.3mg/kg up to10mg/kg,as well as dose expansion stage with recommended dose level from dose escalation stage.
Study: NCT05578443
Drug: 10g Astragalus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus tablets 10g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
Study: NCT05578443
Drug: 20g Astragalus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus tablets 20g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
Study: NCT05395052
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lympho-conditioning agent
Study: NCT06657079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline inhaler
Study: NCT05226533
Drug: DWRX2003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of DWRX2003
Study: NCT05226533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of placebo
Study: NCT06548906
Drug: GZR4 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: GZR4 Injection administered sc, once weekly.
Study: NCT05032859
Drug: vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied topically once daily
Study: NCT06061575
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fever will be managed with acetaminophen
Study: NCT06061575
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fever will be managed with ibuprofen
Study: NCT05089942
Drug: Recombinant Human Insulin Patch ZJSRM2021
Approvals — FDA: no, EMA: no, PMDA: no
Description: health subjects receive recombinant human insulin patch ZJSRM2021，diabetic patients receive recombinant human insulin patch ZJSRM2021（low-dosage or high dosage）
Study: NCT05089942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: health subjects receive placebo patch
Study: NCT05342194
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles
Study: NCT05342194
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo po QD continuously
Study: NCT05944510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo will be administered along with Clozapine (standard of care) in treatment resistant schizophrenia.
Study: NCT05153317
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination granules or tablets for oral administration.
Study: NCT06369012
Drug: Mefenamic acid 500 mg
Normalized name: mefenamic acid 500 MG
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To compare the effectiveness of mefenamic acid versus tranexamic acid in the management of abnormal uterine bleeding.
Study: NCT05048719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05048719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT06114173
Drug: Cardunilizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardunolizumab 6mg/kg was administered every 2 weeks, with the first evaluation at 8 weeks of treatment and subsequent evaluations every 12 weeks.
Study: NCT05411913
Drug: GoodFOR Pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: GoodFOR Pain is a FDA registered topical analgesic.
Study: NCT05411913
Drug: Bengay
Normalized name: BENGAY Ultra
Approvals — FDA: no, EMA: no, PMDA: no
Description: a FDA OTC registered topical analgesic.
Study: NCT05411913
Drug: CBD Clinic Muscle and Joint Pain Relief Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: a non FDA registered topical analgesic.
Study: NCT05411913
Drug: CBD FX CBD Muscle and Joint Cream: Cooling Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: a non FDA registered topical analgesic.
Study: NCT05411913
Drug: Essential Wholesale Muscle Gel
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: a non FDA registered topical analgesic.
Study: NCT05411913
Drug: Extract Labs Muscle Cream
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: a non FDA registered topical analgesic.
Study: NCT05020444
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion
Study: NCT05826119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
Study: NCT06054698
Drug: HRS9531 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531 injection , QW，36 weeks
Study: NCT06054698
Drug: HRS9531 injection Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531 injection Placebo，QW，36 weeks
Study: NCT05486728
Drug: SHJ002/Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ophthalmic
Study: NCT05866172
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4mg iv.drip